Ignet

Gene Information

Gene symbol: ISG15

Gene name: ISG15 ubiquitin-like modifier

HGNC ID: 4053

Synonyms: IFI15, UCRP

Related Genes

#	Gene Symbol	Number of hits
1	CD70	1 hits
2	CD80	1 hits
3	CD8A	1 hits
4	CYBB	1 hits
5	ERBB2	1 hits
6	IFIT1	1 hits
7	IFIT5	1 hits
8	IFNG	1 hits
9	IFNGR1	1 hits
10	IFNGR2	1 hits
11	IKBKG	1 hits
12	IL12B	1 hits
13	IL12RB1	1 hits
14	IL1A	1 hits
15	IL1R1	1 hits
16	IL1R2	1 hits
17	IL6	1 hits
18	IRF8	1 hits
19	PGR	1 hits
20	RPS27A	1 hits
21	RSAD2	1 hits
22	STAT1	1 hits
23	STAT2	1 hits

Related Sentences

#	PMID	Sentence
1	16379000	Upregulated transcripts correlated with genes implicated in immune responses, including those encoding interleukin-1 receptor 2 (IL-1R2), IL-6, ISG-15, CD-80, and TNFSF7.
2	16379000	NYVAC infection also stimulated the expression of NF-kappaB1 and NF-kappaB2 as well as that of NF-kappaB target genes.
3	17449275	Specifically, five genes (Interferon-stimulated gene, 15kDa (ISG15), Interferon-stimulated gene, 56kDa (ISG56), Mx and two unknown genes) were strongly induced after injection by the pHRV-G but not pHRV-N and three of these genes are known as type I IFN-inducible genes.
4	20739522	Porcine reproductive and respiratory syndrome virus inhibits type I interferon signaling by blocking STAT1/STAT2 nuclear translocation.
5	20739522	The transcript levels of IFN-stimulated genes ISG15 and ISG56 and protein level of signal transducer and activator of transcription 2 (STAT2) in PRRSV VR2385-infected MARC-145 cells were significantly lower than those in mock-infected cells after IFN-α treatment.
6	20739522	IFN-induced phosphorylation of both STAT1 and STAT2 and their heterodimer formation in the PRRSV-infected cells were not affected.
7	20739522	However, the majority of the STAT1/STAT2/IRF9 (IFN regulatory factor 9) heterotrimers remained in the cytoplasm of PRRSV-infected cells, which indicates that the nuclear translocation of the heterotrimers was blocked.
8	20739522	Overexpression of NSP1β of PRRSV VR2385 inhibited expression of ISG15 and ISG56 and blocked nuclear translocation of STAT1, which suggests that NSP1β might be the viral protein responsible for the inhibition of IFN signaling.
9	20739522	These findings suggest that PRRSV interferes with the activation and signaling pathway of type I IFNs by blocking ISG factor 3 (ISGF3) nuclear translocation.
10	20739522	Porcine reproductive and respiratory syndrome virus inhibits type I interferon signaling by blocking STAT1/STAT2 nuclear translocation.
11	20739522	The transcript levels of IFN-stimulated genes ISG15 and ISG56 and protein level of signal transducer and activator of transcription 2 (STAT2) in PRRSV VR2385-infected MARC-145 cells were significantly lower than those in mock-infected cells after IFN-α treatment.
12	20739522	IFN-induced phosphorylation of both STAT1 and STAT2 and their heterodimer formation in the PRRSV-infected cells were not affected.
13	20739522	However, the majority of the STAT1/STAT2/IRF9 (IFN regulatory factor 9) heterotrimers remained in the cytoplasm of PRRSV-infected cells, which indicates that the nuclear translocation of the heterotrimers was blocked.
14	20739522	Overexpression of NSP1β of PRRSV VR2385 inhibited expression of ISG15 and ISG56 and blocked nuclear translocation of STAT1, which suggests that NSP1β might be the viral protein responsible for the inhibition of IFN signaling.
15	20739522	These findings suggest that PRRSV interferes with the activation and signaling pathway of type I IFNs by blocking ISG factor 3 (ISGF3) nuclear translocation.
16	22057675	The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.
17	22057675	ISG15 is a small ubiquitin-like protein regulated by type-I interferon and classically associated with viral defense.
18	22057675	Elevated ISG15 expression in breast cancer is especially well documented and is independent of HER2, progesterone receptor, and estrogen receptor status.
19	22057675	We demonstrate that vaccination against ISG15 results in significant CD8-mediated reductions in both primary and metastatic mammary tumor burden.
20	22057675	The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.
21	22057675	ISG15 is a small ubiquitin-like protein regulated by type-I interferon and classically associated with viral defense.
22	22057675	Elevated ISG15 expression in breast cancer is especially well documented and is independent of HER2, progesterone receptor, and estrogen receptor status.
23	22057675	We demonstrate that vaccination against ISG15 results in significant CD8-mediated reductions in both primary and metastatic mammary tumor burden.
24	22057675	The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.
25	22057675	ISG15 is a small ubiquitin-like protein regulated by type-I interferon and classically associated with viral defense.
26	22057675	Elevated ISG15 expression in breast cancer is especially well documented and is independent of HER2, progesterone receptor, and estrogen receptor status.
27	22057675	We demonstrate that vaccination against ISG15 results in significant CD8-mediated reductions in both primary and metastatic mammary tumor burden.
28	22057675	The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.
29	22057675	ISG15 is a small ubiquitin-like protein regulated by type-I interferon and classically associated with viral defense.
30	22057675	Elevated ISG15 expression in breast cancer is especially well documented and is independent of HER2, progesterone receptor, and estrogen receptor status.
31	22057675	We demonstrate that vaccination against ISG15 results in significant CD8-mediated reductions in both primary and metastatic mammary tumor burden.
32	24512893	Furthermore, viral DUBs can also remove the protective effect of conjugated ubiquitin-like molecules such as interferon stimulated gene 15 (ISG15).
33	24996122	All three IFN plasmids induced expression of antiviral genes (Mx, Viperin, ISG15 and IFIT5) at the muscle injection site while the control plasmid had little effect.
34	24996122	Injection of IFNc plasmid was found to induce expression of antiviral genes and receptors for virus RNA (RIG-I, TLR3 and TLR7) in head kidney from 1 to at least 8 weeks.
35	25453225	Since 1996, nine MSMD-causing genes, including seven autosomal (IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1, ISG15, and IRF8) and two X-linked (NEMO, and CYBB) genes have been discovered.
36	25453225	These disorders impair the production of (IL12B, IL12RB1, IRF8, ISG15, NEMO) or the response to (IFNGR1, IFNGR2, STAT1, IRF8, CYBB) IFN-γ.
37	25453225	Since 1996, nine MSMD-causing genes, including seven autosomal (IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1, ISG15, and IRF8) and two X-linked (NEMO, and CYBB) genes have been discovered.
38	25453225	These disorders impair the production of (IL12B, IL12RB1, IRF8, ISG15, NEMO) or the response to (IFNGR1, IFNGR2, STAT1, IRF8, CYBB) IFN-γ.
39	25554382	Although the primary function of PLpro and 3CLpro are to process the viral polyprotein in a coordinated manner, PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses.
40	26122932	Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.
41	26122932	ISG15 is an ubiquitin-like protein induced by type I interferon associated with antiviral activity.
42	26122932	Here, we demonstrate the efficacy of ISG15 as a vaccine adjuvant, inducing human papilloma virus (HPV) E7-specific IFNγ responses as well as the percentage of polyfunctional, cytolytic, and effector CD8 T-cell responses.
43	26122932	T-cell depletion coupled with adoptive transfer experiments revealed that ISG15 protective efficacy was CD8 T-cell mediated.
44	26122932	Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.
45	26122932	ISG15 is an ubiquitin-like protein induced by type I interferon associated with antiviral activity.
46	26122932	Here, we demonstrate the efficacy of ISG15 as a vaccine adjuvant, inducing human papilloma virus (HPV) E7-specific IFNγ responses as well as the percentage of polyfunctional, cytolytic, and effector CD8 T-cell responses.
47	26122932	T-cell depletion coupled with adoptive transfer experiments revealed that ISG15 protective efficacy was CD8 T-cell mediated.
48	26122932	Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.
49	26122932	ISG15 is an ubiquitin-like protein induced by type I interferon associated with antiviral activity.
50	26122932	Here, we demonstrate the efficacy of ISG15 as a vaccine adjuvant, inducing human papilloma virus (HPV) E7-specific IFNγ responses as well as the percentage of polyfunctional, cytolytic, and effector CD8 T-cell responses.
51	26122932	T-cell depletion coupled with adoptive transfer experiments revealed that ISG15 protective efficacy was CD8 T-cell mediated.
52	26122932	Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.
53	26122932	ISG15 is an ubiquitin-like protein induced by type I interferon associated with antiviral activity.
54	26122932	Here, we demonstrate the efficacy of ISG15 as a vaccine adjuvant, inducing human papilloma virus (HPV) E7-specific IFNγ responses as well as the percentage of polyfunctional, cytolytic, and effector CD8 T-cell responses.
55	26122932	T-cell depletion coupled with adoptive transfer experiments revealed that ISG15 protective efficacy was CD8 T-cell mediated.